Novel Pharmaceutical Solvent-Water Separation System

描述（由申请人提供）：在第一阶段，我们超过了所有关键目标。在评估异丙醇(IPA)-水分离时，我们证明了在渗透蒸发和蒸汽分离中高膜渗透和高膜分离的结合。膜的稳定性一直是评论界关注的问题，其性能优异，远远优于其他工业膜。CMS膜被证明在130°C和整个组成操作范围内是稳定的。经济评估表明，与现有的干燥工艺相比，CMS膜节省了80%以上的资金。除了对ipa -水的研究外，还对另外两种药用溶剂进行了成功的评价。浸出研究表明，CMS膜是稳定的。基于结果和商业化分析，CMS系统被视为一种平台技术。在医药溶剂回收、加强化学反应、化工溶剂回收、燃料级乙醇制造和稳定工业酯等方面存在重大机遇。有了很多机会，大量的工业和制药公司以及领先的研究人员已经承诺积极参与该计划。这种参与将增加商业化的总体机会。在第二阶段，我们将首先制造高通量复合膜组件。然后，我们将重点演示在渗透蒸发（PV）模式下运行的ipa -水系统。重点将放在PV上，因为这是最终用户最简单的系统。一旦成功获得PV中ipa -水的基本数据，我们将扩展到其他药物溶剂的评估，并在蒸汽分离模式下评估膜。其他升级将包括建模和系统设计，以增强整体净化；长期测试加上延长的溶剂浸出测试；使用商用中空纤维支架开发增强膜组件；建造大型滑橇进行现场测试，并扩大我们的经济评估，以显示替代干燥路线的优越性能。在整个第二阶段，我们将与我们的工业伙伴密切合作。本程序开发了一种低成本，简单，工艺回收医药溶剂。这将鼓励溶剂的重复使用，既环保又具有成本效益。这一过程还将使潜在的生物污染物远离环境。

DESCRIPTION (provided by applicant): In Phase I we exceeded all key objectives. We demonstrated in both pervaporation and vapor separation the combination of high membrane permeation and high membrane separation when evaluating isopropyl alcohol (IPA)-Water separation. Membrane stability, which had been concern of reviewers, was shown to be excellent and far superior to other commercial membranes. CMS membranes were shown to be stable up to 130¿C and over the whole compositional operating range. Economic evaluations showed the CMS membranes to have in excess of 80% capital savings compared to existing drying processes. In addition to work on IPA-water, two other pharmaceutical solvents were successfully evaluated. Leaching studies have shown the CMS membranes to be stable. Based on results and commercialization analysis the CMS system is seen as a platform technology. Significant opportunities exist in pharmaceutical solvent recovery enhancing chemical reactions, chemical industry solvent recovery, manufacture of fuel grade ethanol and stabilizing industrial esters. With many opportunities, a large number of industrial and pharmaceutical companies as well as leading researchers have committed to actively participate in this program. This participation will enhance overall chances for commercialization. In Phase II we will first fabricate high flux composite membrane modules. Then we would focus our demonstration on IPA-water systems operating in pervaporation (PV) mode. Focus will be on PV since this is the simplest system for the end user. Once successful basic data on IPA-water in PV is obtained we will expand the evaluation to other pharmaceutical solvents and also evaluating membranes in the vapor separation mode. Additional upgrades will include modeling and system design to enhance overall purification; long term testing plus extended solvent leaching tests; develop enhanced membrane modules using commercial hollow fiber supports; building large skid for field testing and expanding our economic evaluation to show superior performance to alternative drying routes. Throughout this Phase II we will work closely with our industrial partners. This program develops a low cost, simple, process to recover pharmaceutical solvents. This will encourage solvent reuse which is environmentally attractive and cost effective. The process will also keep potential biological contaminants out of the environment.